Determinations of mifepristone and its metabolites and their pharmacokinetics in healthy female Chinese subjects

Yaoxue Xuebao

Volumn 46, Issue 10, 2011, Pages 1241-1245

  Teng, Yan Ni ^a,b   Dong, Rui Qian ^c   Wang, Ben Jie ^b   Liu, Huan Jun ^b   Jiang, Zhi Mei ^b   Wei, Chun Min ^b   Zhang, Rui ^b   Yuan, Gui Yan ^b   Liu, Xiao Yan ^b   Guo, Rui Chen ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c Maternity and Child Care Centre of Jinan   (China)

Author keywords

C hydroxylated mifepristone; Di demethylated mifepristone; Mifepristone; Mono demethylated mifepristone; Pharmacokinetics

Indexed keywords

ACETIC ACID ETHYL ESTER; DRUG METABOLITE; MIFEPRISTONE;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; DATA ANALYSIS SOFTWARE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; SENSITIVITY ANALYSIS;

ADMINISTRATION, ORAL; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MIFEPRISTONE; TABLETS;

EID: 83455230693     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Bertagna X, Bertagna C, Luton JP, et al. The new steroid analog RU486 inhibits glucocorticoid action in man [J]. J Clin Endocrinol Metab, 1984, 59: 25-28. (Pubitemid 14087519)
2. Gemzell-Danielsson K, Westlund P, Johannisson E, et al. Effect of low weekly doses of mifepristone on ovarian function and endometrial development [J]. Hum Reprod, 1996, 11: 256-264. (Pubitemid 26089170)
3. Prange-Kiel J, Rune GM, Wallwiener D, et al. Inhibition of proliferation and differentiation by RU486 in human endometrial stromal and epithelial cells in vitro [J]. Exp Clin Endocrinol Diabetes, 2000, 108: 275-281. (Pubitemid 30458598)
4. Chasserot-Golaz S, Beck G. How the potency of the steroid RU486 is related to P450 activities induced by dexamethasone and phenobarbital in rat hepatoma cells [J]. J Steroid Biochem Mol Biol, 1992, 41: 653-657.
5. Jang GR, Wrighton SA, Benet LZ. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU486) oxidation in human liver microsomes [J]. Biochem Pharmacol, 1996, 52: 753-761. (Pubitemid 26276491)
6. Jang GR, Benet LZ. Antiprogestin-mediated inactivation of cytochrome P450 3A4 [J]. Pharmacology, 1998, 56: 150-157. (Pubitemid 28075357)
7. Reilly PE, Gomi RJ, Mason SR. Mechanism-based inhibition of rat liver microsomal diazepam C3-hydroxylase by mifepristone associated with loss of spectrally detectable cytochrome P450 [J]. Chem Biol Interact, 1999, 118: 39-49. (Pubitemid 29112820)
8. Khan KK, He YQ, Correia MA, et al. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4 [J]. Drug Metab Dispos, 2002, 30: 985-990.
9. Lin HL, Zhang HM, Hollenberg PF. Metabolic activation of mifepristone [RU486; 17β-hydroxy-11β-(4-dimethylaminophenyl)-17α-(1-propynyl) -estra-4, 9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6 [J]. J Pharmacol Exp Ther, 2009, 329: 26-37.